Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARE-PDM1 in Primary Dysmenorrhea
NCT05752526Phase 1Completed
- Sponsor
- Daré Bioscience, Inc.
- Start
- May 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of diclofenac in primary dysmenorrhea (PD) (3 arms), sponsored by Daré Bioscience, Inc. Primary endpoints: Systemic Level of Diclofenac in Plasma at 7 days, Vaginal Fluid levels of diclofenac at 3 days and 2 more. Started May 2023; status: completed.
02
Drugs
diclofenac
03
Conditions
primary dysmenorrhea (PD)
Beyond the preview
Go deeper on NCT05752526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05752526.